Everolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclasts

Bone

Volumn 35, Issue 5, 2004, Pages 1144-1156

  Kneissel, Michaela ^a   Luong Nguyen, Ngoc Hong ^a   Baptist, Myma ^a   Cortesi, Reto ^a   Zumstein Mecker, Sabine ^a   Kossida, Sophia ^a   O'Reilly, Terry ^a   Lane, Heidi ^a   Susa, Mira ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Bone resorption; Cathepsin K; Osteoclast; Ovariectomy; S6 kinase

Indexed keywords

ACID PHOSPHATASE; CATHEPSIN K; EVEROLIMUS; S6 KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCELLOUS BONE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL PROTECTION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG INHIBITION; DRUG POTENCY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME DEGRADATION; ENZYME INHIBITION; IC 50; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; OVARIECTOMY; TREATMENT INDICATION;

3T3 CELLS; ANIMALS; APOPTOSIS; BODY WEIGHT; BONE AND BONES; BONE DENSITY; BONE RESORPTION; CALCIFICATION, PHYSIOLOGIC; CATHEPSINS; CELL DIFFERENTIATION; CELL LINE; CELL PROLIFERATION; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GROWTH INHIBITORS; HUMANS; MICE; MICE, INBRED C57BL; OSTEOCLASTS; OVARIECTOMY; PROTEIN KINASES; RATS; RIBOSOMAL PROTEIN S6 KINASES; SIROLIMUS;

EID: 8444225722     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2004.07.013     Document Type: Article

References (37)

1. R.T. Abraham Identification of TOR signaling complexes: More TORC for the cell growth engine Cell 111 2002 9 12
2. V. Besset, K. Rhee, and D.J. Wolgemuth The identification and characterization of expression of Pftaire-1, a novel Cdk family member, suggest its function in the mouse testis and nervous system Mol. Reprod. Dev. 50 1998 18 29
3. I. Beuvink, T. O'Reilly, S. Zumstein-Mecker, F. Zilbermann, R. Sedrani, and S.C. Kozma Antitumor activity of RAD001, an orally active rapamycin derivative Proc. Am. Assoc. Cancer Res. 42 2001 [abstract 1972]
4. A. Boulay, S. Zumstein-Mecker, C. Stephan, I. Beuvink, F. Zilbermann, and R. Haller Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of S6K1 in peripheral blood mononuclear cells Cancer Res. 64 2004 252 261
5. D. Cappellen, N.H. Luong-Nguyen, S. Bongiovanni, O. Grenet, C. Wanke, and M. Susa Transcriptional program of mouse osteoclast differentiation governed by the macrophage colony-stimulating factor and the ligand for the receptor activator of NF κB J. Biol. Chem. 277 2002 21971 21982
6. H. Glantschnig, J.E. Fisher, G. Wesolowski, G.A. Rodan, and A.A. Reszka M-CSF, TNF alpha and RANKL promote osteoclast survival by signaling through mTOR/S6 kinase Cell Death Differ. 10 2003 1165 1177
7. S.R. Goldring Inflammatory mediators as essential elements in bone remodeling Calcif. Tissue Int. 73 2003 97 100
8. G.R. Goodman, I.R. Dissanayake, B.R. Sodam, E. Gorodetsky, J. Lu, and Y.F. Ma Immunosuppressant use without bone loss-implications for bone loss after transplantation J. Bone Miner. Res. 16 2001 72 78
9. M. Guba, P. von Breitenbuch, M. Steinbauer, G. Koehl, S. Flegel, and M. Hornung Rapamycin inhibits primary and metastatic tumor growth by angiogenesis: involvement of vascular endothelial growth factor Nat. Med. 8 2002 128 135
10. P.G. Hogan, L. Chen, J. Nardone, and A. Rao Transcriptional regulation by calcium, calcineurin, and NFAT Genes Dev. 17 2003 2205 2232
11. S. Huang, and P.J. Houghton Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic Curr. Opin. Invest. Drugs 3 2002 295 304
12. C.C. Hudson, M. Liu, G.G. Chiang, D.M. Otterness, D.C. Loomis, and F. Kaper Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin Mol. Cell. Biol. 22 2002 7004 7014
13. E. Jacinto, and M.N. Hall Tor signalling in bugs, brain and brawn Nat. Rev., Mol. Cell Biol. 4 2003 117 126
14. H.A. Lane, A. Boulay, M. Hattenberger, S.-M. Maira, G. Thomas, and A. Merlo The orally active rapamycin derivative RAD001 has potential as an antitumor agent with a broad antiproliferative activity: PTEN as a molecular determinant of response Proc. Am. Assoc. Cancer Res. 44 2003 314
15. M. Li, Y. Shen, and T.J. Wronski Time course of femoral neck osteopenia in ovariectomized rats Bone 20 1997 55 61
16. A. Lo, and R.R. Alloway Strategies to reduce toxicities and improve outcomes in renal transplant patients Pharmacotherapy 22 2002 316 328
17. K.A. Martin, and J. Blenis Coordinate regulation of translation by the PI 3-kinase and mTOR pathways Adv. Cancer Res. 86 2002 1 39
18. K. Matsuzaki, N. Udagawa, N. Takahashi, K. Yamaguchi, H. Yasuda, and N. Shima Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures Biochem. Biophys. Res. Commun. 246 1998 199 204
19. K. Migita, K. Eguchi, T. Aoyagi, T. Tsukada, M. Tsuboi, and Y. Kawabe The effects of the immunosuppressant rapamycin on the growth of rheumatoid arthritis (RA) synovial fibroblast Clin. Exp. Immunol. 104 1996 86 91
20. S.C. Miller, and T. Wronski Long-term osteopenic changes in cancellous bone structure in ovariectomized rats Anat. Rec. 236 1993 433 441
21. M. Missbach, M. Jeschke, J. Feyen, K. Muller, M. Glatt, and J. Green A novel inhibitor of the tyrosine kinase Src suppresses phosphorylation of its major cellular substrates and reduces bone resorption in vitro and in rodent models in vivo Bone 24 1999 437 449
22. M.M. Mita, A. Mita, and E.K. Rowinsky Mammalian target of rapamycin: a new molecular target for breast cancer Clin. Breast Cancer 4 2003 126 137
23. B. Nashan Early clinical experience with a novel rapamycin derivative Ther. Drug Monit. 24 2002 53 58
24. T. O'Reilly, J. Vaxelaire, M. Muller, H.H. Fiebig, M. Hattenberger, and H.A. Lane In vivo activity of RAD001, an orally active rapamycin derivative, in experimental tumor models Proc. Am. Assoc. Cancer Res. 43 2002 71
25. A.M. Parfitt, M.K. Drezner, F.H. Glorieux, J.A. Kanis, H. Malluche, and P.J. Meunier Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee J. Bone Miner. Res. 2 1987 595 610
26. V. Shalhoub, J. Faust, W.J. Boyle, C.R. Dunstan, M. Kelley, and S. Kaufman Osteoprotegerin and osteoprotegerin ligand effects on osteoclast formation from human peripheral blood mononuclear cell precursors J. Cell. Biochem. 72 1999 251 261
27. N.K. Shevde, A.C. Bendixen, K.M. Dienger, and J.W. Pike Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression Proc. Natl. Acad. Sci. U. S. A. 97 2000 7829 7834
28. C. Shui, B.L. Riggs, and S. Khosla The immunosuppressant rapamycin, alone or with transforming growth factor-beta, enhances osteoclast differentiation of RAW264.7 monocyte-macrophage cells in the presence of RANK-ligand Calcif. Tissue Int. 71 2002 437 446
29. S.M. Sprague Mechanism of transplantation-associated bone loss Pediatr. Nephrol. 14 2000 650 653
30. H. Sudo, H.-A. Kodama, Y. Amagai, S. Yamamoto, and S. Kasai In vitro differentiation and calcification in a new clonal osteogenic cell line derived from newborn mouse calvaria J. Cell Biol. 96 1983 191 198
31. M. Susa, N.-H. Luong-Nguyen, D. Cappellen, N. Zamurovic, and R. Gamse Human primary osteoclasts: in vitro generation and applications as pharmacological and clinical assay J. Transp. Med. 2 2004 6
32. S. Taesch, and D. Niese Safety and tolerability of new oral formulation of cyclosporin A, Sandimmun Neoral, in renal transplant patients Transpl. Int. 7 Suppl 1 1994 S263 S266
33. S.L. Teitelbaum Bone resorption by osteoclasts Science 289 2000 1504 1508
34. E.F. Wagner Functions of AP1 (Fos/Jun) in bone development Ann. Rheum. Dis. 61 Suppl 2 2002 ii40 ii42
35. T.J. Wronski, L.M. Dann, K.S. Scott, and M. Cintron Long-term effects of ovariectomy and aging on the rat skeleton Calcif. Tissue Int. 45 1989 360 366
36. D.S. Yamashita, and R.A. Dodds Cathepsin K and the design of inhibitors of cathepsin K Curr. Pharm. Des. 6 2000 1 24
37. T. Yang, and J.Y. Chen Identification and cellular localization of human PFTAIRE1 Gene 267 2001 165 172